Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| John Gordon | M | - |
Celentyx Ltd.
 Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom.
University of Birmingham
| 20 jaar |
| Priscilla Snowball | F | 65 |
University of Birmingham
| - |
| Catherine A. Brady | M | - |
Celentyx Ltd.
Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | - |
| N. Dominic Cadbury | M | 84 |
University of Birmingham
| - |
| David Coleman | M | - |
University of Birmingham
| 14 jaar |
| Allan Tait | M | - |
University of Birmingham
| - |
| Gideon Hirschfield | M | - |
University of Birmingham
| 12 jaar |
| Rosemary Harris | F | 66 |
University of Birmingham
| - |
| Martin Devenish | M | - |
University of Birmingham
| - |
| John Curnow | M | - |
Celentyx Ltd.
Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | - |
| Jonathan Mercer Watkins | M | - |
University of Birmingham
| - |
| Charles Penn | M | - |
University of Birmingham
| - |
| Richard Williams | M | - |
University of Birmingham
| - |
| Amy S. Butler | M | - |
The International Union of Basic & Clinical Pharmacology
| - |
| Jim Glover | M | 80 |
University of Birmingham
| - |
| Chris H. Colecchi | M | - |
University of Birmingham
| - |
| Alan Keith Boyd | M | 70 |
Celentyx Ltd.
Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | - |
| Lorenzo Apicella | M | - |
University of Birmingham
| - |
| Karan Faridoon Bilimoria | M | 63 |
University of Birmingham
| - |
| David Logan | M | 81 |
University of Birmingham
| - |
| Lisa Fretwell | F | 54 |
University of Birmingham
| - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigd Koninkrijk | 20 | 95.24% |
| Verenigde Staten | 1 | 4.76% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Nicholas Mark Barnes
- Persoonlijk netwerk
